IL17A and neoplasm: In a phase I clinical trial for multiple myeloma, patients are being examined to determine if anti-IL-17 mAb CJM112, either alone or in combination with anti-PD-1, is an effective treatment option to restore the immune response and favoring the apoptosis of tumor cells [103].